What is the current value of beta-adrenoreceptor antagonists for angina?

References

• GBD 2015 Mortality and Causes of DeathCollaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016 Oct 8;388(10053):1459–1544.
   PubMed Web of Science ®Google Scholar
• Husted SE, Ohman EM. Pharmacological and emerging therapies in the treatment of chronic angina. Lancet. 2015 Aug 15;386(9994):691–701.
   PubMed Web of Science ®Google Scholar
• Ko DT, Hebert PR, Coffey CS, et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. Jama. 2002 Jul 17;288(3):351–357.
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Chiu N, Pankayatselvan V, et al. Prevalence of angina and use of medical therapy among US adults: a nationally representative estimate. Am Heart J. 2020 Oct;228:44–46.
   PubMed Web of Science ®Google Scholar
• Frishman WH, Heiman M, Soberman J, et al. Comparison of celiprolol and propranolol in stable angina pectoris. Celiprolol international angina study group. Am J Cardiol. 1991 Apr 1;67(8):665–670.
   PubMed Web of Science ®Google Scholar
• Oh PC, Kang WC, Moon J, et al. Anti-Anginal and metabolic effects of carvedilol and atenolol in patients with stable angina pectoris: a prospective, randomized, parallel, open-label study. Am J Cardiovasc Drugs. 2016 Jun;16(3):221–228.
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Cohn PF, Deedwania PC, et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The atenolol silent ischemia study (ASIST). Circulation. 1994 Aug;90(2):762–768.
   PubMed Web of Science ®Google Scholar
• Fox KM, Mulcahy D, Findlay I, et al. The total ischaemic burden European trial (Tibet). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The Tibet Study Group. Eur Heart J. 1996 Jan;17(1):96–103.
   PubMed Web of Science ®Google Scholar
• de Vries RJ, van Den Heuvel AF, Lok DJ, et al. Nifedipine gastrointestinal therapeutic system versus atenolol in stable angina pectoris. The Netherlands working group on cardiovascular research (WCN). Int J Cardiol. 1996 Dec 6;57(2):143–150.
   PubMedGoogle Scholar
• van de Ven LL, Vermeulen A, Tans JG, et al. Which drug to choose for stable angina pectoris: a comparative study between bisoprolol and nitrates. Int J Cardiol. 1995 Jan 6;47(3):217–223.
   PubMed Web of Science ®Google Scholar
• Savonitto S, Ardissiono D, Egstrup K, et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the International multicenter angina exercise (IMAGE) study. J Am Coll Cardiol. 1996 Feb;27(2):311–316.
   PubMed Web of Science ®Google Scholar
• Sabidó M, Thilo H, Guido G. Long-term effectiveness of bisoprolol in patients with angina: a real-world evidence study. Pharmacol Res. 2019 Jan;139:106–112.
   PubMed Web of Science ®Google Scholar
• Dézsi CA, Szentes V. The real role of β-blockers in daily cardiovascular therapy. Am J Cardiovasc Drugs. 2017;17(5):361–373.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Bhatt DL, Steg PG, et al. β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circ Cardiovasc Qual Outcomes. 2014 Nov;7(6):872–881.
   PubMed Web of Science ®Google Scholar
• Vokó Z, de Brouwer S, Lubsen J, et al. Long-term impact of secondary preventive treatments in patients with stable angina. Eur J Epidemiol. 2011 May;26(5):375–383.
   PubMed Web of Science ®Google Scholar
• Shu de F, Dong BR, Lin XF, et al. Long-term beta blockers for stable angina: systematic review and meta-analysis. Eur J Prev Cardiol. 2012 Jun;19(3):330–341.
   PubMed Web of Science ®Google Scholar
• Fox KM, Chopra MP, Portal RW, et al. Long-term beta blockade: possible protection from myocardial infarction. Br Med J. 1975;1(5950):117–119.
   PubMedGoogle Scholar
• Nidorf SM, Parsons RW, Thompson PL, et al. Reduced risk of death at 28 days in patients taking a beta blocker before admission to hospital with myocardial infarction. Br Med J. 1990;300(6717):71–74.
   PubMedGoogle Scholar
• Heusch G, Gersh BJ. The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge. Eur Heart J. 2016;38(11):774–784.
   Web of Science ®Google Scholar
• Kern MJ, Ganz P, Horowitz JD, et al. Potentiation of coronary vasoconstriction by beta-adrenergic blockade in patients with coronary artery disease. Circulation. 1983 Jun;67(6):1178–1185.
   PubMed Web of Science ®Google Scholar
• Izzo P, Macchi A, De Gennaro L, et al. Recurrent angina after coronary angioplasty: mechanisms, diagnostic and therapeutic options. Eur Heart J Acute Cardiovasc Care. 2012 Jun;1(2):158–169.
   PubMedGoogle Scholar
• Ferrari R, Pavasini R, Pg C, et al. Anti-anginal drugs–beliefs and evidence: systematic review covering 50 years of medical treatment. Eur Heart J. 2018;40(2): 190–194.
   Web of Science ®Google Scholar
• Tendera M, Fox K, Ferrari R, et al. Inadequate heart rate control despite widespread use of beta-blockers in outpatients with stable CAD: findings from the international prospective CLARIFY registry. Int J Cardiol. 2014 Sep;176(1):119–124.
   PubMed Web of Science ®Google Scholar
• White HD, Lowe JB. Antianginal efficacy of perhexiline maleate in patients refractory to beta-adrenoreceptor blockade. Int J Cardiol. 1983 May;3(2):145–155.
   PubMed Web of Science ®Google Scholar
• Cole PL, Beamer AD, McGowan N, et al. Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel anti-anginal agent. Circulation. 1990 Apr;81(4):1260–1270.
   PubMed Web of Science ®Google Scholar
• Glezer M. Trimetazidine and bisoprolol to treat angina in symptomatic patients: post hoc analysis from the CHOICE-2 study. Cardiol Ther. 2021 Jun;10(1):161–173.
   PubMed Web of Science ®Google Scholar
• Gilarevskii SR, Lantsova EV, Akimov AA. Efficacy and safety of combined treament with ivabradine and metoprolol in patients with stable angina pectoris - a systematic review. Kardiologiia. 2020 Dec 15;60(11):1357.
   PubMed Web of Science ®Google Scholar
• Steinman MA, Zullo AR, Lee Y, et al. Association of β-blockers with functional outcomes, death, and rehospitalization in older nursing home residents after acute myocardial infarction. JAMA Intern Med. 2017;177:254–262.
   PubMed Web of Science ®Google Scholar
• Ferrari R, Camici PG, Crea F, et al. Expert consensus document: a ‘diamond’ approach to personalized treatment of angina. Nat Rev Cardiol. 2018 Feb;15(2):120–132.
   PubMedGoogle Scholar